Geode Capital Management LLC Purchases 32,614 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC)

Geode Capital Management LLC grew its position in shares of Century Therapeutics, Inc. (NASDAQ:IPSC) by 3.5% during the third quarter, according to its most recent filing with the SEC. The firm owned 968,182 shares of the company’s stock after acquiring an additional 32,614 shares during the period. Geode Capital Management LLC owned about 1.14% of Century Therapeutics worth $1,656,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Barclays PLC grew its stake in Century Therapeutics by 283.6% in the third quarter. Barclays PLC now owns 61,945 shares of the company’s stock worth $106,000 after purchasing an additional 45,797 shares during the period. Wellington Management Group LLP bought a new stake in shares of Century Therapeutics during the 3rd quarter valued at $284,000. State Street Corp boosted its holdings in shares of Century Therapeutics by 7.4% during the 3rd quarter. State Street Corp now owns 836,914 shares of the company’s stock valued at $1,431,000 after buying an additional 57,323 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Century Therapeutics in the 3rd quarter worth about $27,000. Finally, Renaissance Technologies LLC increased its stake in shares of Century Therapeutics by 6.1% in the 2nd quarter. Renaissance Technologies LLC now owns 165,500 shares of the company’s stock worth $422,000 after acquiring an additional 9,500 shares in the last quarter. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Price Performance

Shares of NASDAQ:IPSC opened at $1.07 on Thursday. The stock’s fifty day moving average price is $1.26 and its 200-day moving average price is $1.67. Century Therapeutics, Inc. has a 1 year low of $0.95 and a 1 year high of $5.51. The company has a market cap of $90.98 million, a P/E ratio of -0.58 and a beta of 1.76.

Century Therapeutics (NASDAQ:IPSC) last issued its earnings results on Tuesday, November 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.08. The company had revenue of $0.79 million for the quarter, compared to analysts’ expectations of $0.47 million. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. During the same quarter last year, the company posted ($0.55) earnings per share. On average, sell-side analysts anticipate that Century Therapeutics, Inc. will post -1.63 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. HC Wainwright cut their price objective on shares of Century Therapeutics from $9.00 to $5.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Chardan Capital reduced their price objective on Century Therapeutics from $17.00 to $11.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Finally, Piper Sandler lowered their price objective on Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating for the company in a research note on Monday, December 30th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $10.00.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.